Phase

Unity Biotechnology announces positive data in phase 2 BEHOLD study of UBX1325 in patients with DME

Unity Biotechnology announces positive data in phase 2 BEHOLD study of UBX1325 in patients with DME

Unity Biotechnology Inc. today announced 12- and 18-week data from its Phase 2 BEHOLD study of UBX1325, a senolytic Bcl-xL inhibitor, in patients with diabetic macular edema (DME). During a conference call held today, Unity officials detailed Phase 2 BEHOLD DME study (NCT04857996) 12- and 18-week data. “We have achieved a strong proof of concept …

Unity Biotechnology announces positive data in phase 2 BEHOLD study of UBX1325 in patients with DME Read More »

Hidden Quantum Phase in 2D Crystal

Mysterious Hidden Quantum Phase in a 2D Crystal Captured by Scientists for the First Time

This illustration represents the light-induced collapse of the nanoscale charge order in a 2D crystal of tantalum disulfide (star-shapes) and the generation of a hidden metastable metallic state (spheres). Credit: Frank Yi Gao Single-shot spectroscopy techniques provide scientists with a new understanding of a mysterious light-driven process. Harold “Doc” Edgerton, the late

Innovent and Laekna Jointly Announce First Patient Dosed with Three-drug Combination in a Phase 1/2 Study for the Treatment of Patients with Solid Tumors Who Were Resistant to Prior Anti-PD-1/PD-L1 Therapy

SAN FRANCISCO and SUZHOU, China, July 31, 2022 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic, ophthalmology and other major diseases, and Laekna Therapeutics, a clinical-stage biotechnology company dedicated to bringing ground-breaking therapies to cancer and liver …

Innovent and Laekna Jointly Announce First Patient Dosed with Three-drug Combination in a Phase 1/2 Study for the Treatment of Patients with Solid Tumors Who Were Resistant to Prior Anti-PD-1/PD-L1 Therapy Read More »